Servier is at the scientific cutting edge in oncology, with internal research focused on discovery of new molecules restoring apoptosis in cancer cells. We are now investigating our BCL-2 inhibitors in various hematological malignancies. Our MCL1 inhibitor will be in the clinic soon.
With its industrial and academic partners, Servier is strongly engaged in immuno-oncology. Two bispecific T-cell engager antibodies are already in the clinic in liquid and solid tumors. Our allogeneic CART T-cell based therapy is about to start its first in human program in adults and children with acute lymphoblastic leukemia.
Our portfolio also includes cytotoxics developed in lymphoma and colorectal cancer and Tyrosine Kinase Inhibitors in breast, and lung cancers.
From the bench to the clinic and back to the bench, translational science is integrated in all stages of our research. In our biomarker program we are constantly looking to improve the selectivity of our treatments for better efficacy. We are also striving to uncover synergetic treatment combinations between our molecules or with existing therapeutic options.

We strongly believe the future of Oncology resides in providing patients with personalized treatments based on individual cancer care. This means yielding treatment using the right drug, at the right time for the right person. To answer this challenge, we have been building a diversified and innovative portfolio that focuses on small molecules, engineered antibodies, and cell therapy for the treatment of both hematological malignancies and solid tumors.

We currently have eight new molecular entities in clinical development, and two more in pre-clinical development.

Our key strength inheres in our in-depth experience in major cancer pathways: apoptosis evasion, proliferation, epigenetics, and immune protection; along with a growing experience in clinical development for lymphoma, leukemia, breast cancer and non-small cell lung cancer.

Today there are three pillars to our research in oncology: Apoptosis, immuno-oncology, and proliferation and differentiation. Though, our long-term strategic focus is on Apoptosis, and immune-oncology.

– Induction of apoptosis

Inducing cancer cells death using a natural physiological process

Servier has over 10 years of in-house expertise in the research of apoptosis. It is one of the hallmarks of cancer, and is also a common mechanism of resistance to drug treatment.

We strongly believe in the great potential of treatment development represents in the field of apoptosis. Since 2007, we have been working in partnership with Vernalis on an agent targeting Bcl-2 inhibitors which entered clinical development in 2012 (1). And since May 2014, we have been collaborating with Novartis for the development and commercialization of specific Bcl-2 inhibitors, and anti-Mcl-1 drugs candidates. Both hematological malignancies and solid tumors could be targeted by these novel drug candidates. (2)

– Immuno-oncology

Using the body’s immune system to help fight cancer

Servier strongly believe in immuno-oncology as being the cornerstone of cancer therapy alongside surgery, chemotherapy, radiotherapy and targeted therapies.

Since 2011, we have engaged in cutting-edge research in partnership with MacroGenics, Inc. to develop engineered antibodies known as Dual-Affinity Re-Targeting (DART™). The DART technology is a proprietary, bi-specific antibody platform in which a single recombinant molecule is able to target two different antigens. These DART proteins can be used to redirect the body’s cell-destroying, immune effector cells against tumor cells. (3)

– Proliferation and differentiation

Blocking the enzymes that enable cancer cells growth

Servier has several tyrosine kinase inhibitors currently in clinical development. Since 2013, we have been collaborating with Clovis Oncology on developing Lucitanib, an oral, dual-selective inhibitor of the tyrosine kinase activity for aberrant breast cancer patients currently in clinical development Phase I/II. (4)

 

(1) : Press release 19th June 2014: “Vernalis and Servier achieve Research Milestone as BCL-2 inhibitor drug candidate enters Phase I”
http://www.vernalis.com/media-centre/latest-releases/121-media-centre/2014-releases/684-vernalis-and-servier-achieve-research-milestone-as-bcl-2-inhibitor-drug-candidate-enters-phase-i

(2) : Press release from 7th Dec 2015 “Servier announces expansion of collaboration for the development and commercialization of anticancer drug candidates targeting apoptosis” http://www.servier.com/content/servier-announces-expansion-collaboration-development-and-commercialization-anticancer-drug

(3) : Press release from 20th Sept 2012 “MacroGenics and Servier Enter Broad Strategic Alliance to Develop and Commercialize Three Anti-Cancer DART™ Products“ http://ir.macrogenics.com/releasedetail.cfm?ReleaseID=792696

(4) : Press release from 25th Nov 2013 “Servier will be partnering with Clovis Oncology, an American biopharmaceutical company, for the development of lucitanib”
http://www.servier.com/content/servier-will-be-partnering-clovis-oncology-american-biopharmaceutical-company-development